Athira Pharma (LONA) Stock Price, News & Analysis

Company Overview

Athira Pharma, traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company’s research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.

Athira’s lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer’s disease and related cognitive impairments. Fosgonimeton has advanced through clinical development and has been evaluated in randomized clinical studies; the company also supports a broader discovery and development program that applies the same biological rationale to additional neurodegenerative targets.

The company conducts clinical development activities in the United States and in international sites as part of its trial programs. Athira operates as a research-driven organization with capabilities in small-molecule drug discovery, preclinical neuroscience, and clinical trial execution, and it collaborates with academic and clinical investigators to advance its programs. Public filings and company disclosures provide further detail on its pipeline, regulatory interactions, and study designs for investors and stakeholders.

Key Stats

• Today's Range: $8.37 to $9.10
• 50-Day Range: $7.88 to $11.26
• 52-Week Range: $2.85 to $14.21
• Volume: 19,229 shs
• Average Volume: 14,401 shs
• Market Capitalization: $81.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Hold

Athira Pharma Stock Analysis - MarketRank™

Athira Pharma scored higher than 75% of companies evaluated by MarketBeat, and ranked 30th out of 86 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Athira Pharma has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Athira Pharma has a consensus price target of $15.00, representing about 72.6% upside from its current price of $8.69.

Amount of Analyst Coverage

Athira Pharma has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Athira Pharma are expected to grow in the coming year, from ($3.12) to ($1.48) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Athira Pharma is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Athira Pharma is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Athira Pharma has a P/B Ratio of 2.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.74% of the float of Athira Pharma has been sold short.

Short Interest Ratio / Days to Cover

Athira Pharma has a short interest ratio ("days to cover") of 2.94, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Athira Pharma has recently decreased by 8.77%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Athira Pharma does not currently pay a dividend.

Dividend Growth

Athira Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.34

News Sentiment

Athira Pharma has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.07 average news sentiment score of Manufacturing companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Athira Pharma this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added Athira Pharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Athira Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

25.73% of the stock of Athira Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

57.12% of the stock of Athira Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 6/26/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Biological Products, Except Diagnostic Substances
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LONA
• CIK: 1620463
• Web: N/A
• Phone: (425) 620-8501
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Athira Pharma: $15.00
• High Price Target: $20.00
• Low Price Target: $10.00
• Potential Upside/Downside: +72.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$105.61 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -381.01%
• Return on Assets: -225.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.38
• Quick Ratio: 10.38

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.98 per share
• Price / Book: 2.92

Miscellaneous

• Outstanding Shares: 9,390,000
• Free Float: 6,977,000
• Market Cap: $81.60 million
• Optionable: N/A
• Beta: 1.97